Trade IVERIC bio, Inc. - ISEE CFD
Market information is presented
as of 2023-09-21
- Summary
| Spread | - | ||||||||
|
Long position overnight fee
Long position overnight fee
Go to platform | -0.026151% | ||||||||
|
Short position overnight fee
Short position overnight fee
Go to platform | 0.003929% | ||||||||
| Overnight fee time | 21:00 (UTC) | ||||||||
| Min traded quantity | 1 | ||||||||
| Currency | USD | ||||||||
| Margin | 5% | ||||||||
| Stock exchange | United States of America | ||||||||
| Commission on trade | 0% |
*Information provided by Capital.com
IVERIC bio Inc ESG Risk Ratings
‘C’ score indicates satisfactory relative ESG performance and moderate degree of transparency in reporting material ESG data publicly.
| Prev. Close* | N/A |
| Open* | N/A |
| 1-Year Change* | N/A |
| Day's Range* | N/A |
| 52 wk Range | 8.95-39.72 |
| Average Volume (10 days) | 7.66M |
| Average Volume (3 months) | 96.76M |
| Market Cap | 5.43B |
| P/E Ratio | -100.00K |
| Shares Outstanding | 137.98M |
| Revenue | N/A |
| EPS | -1.76 |
| Dividend (Yield %) | N/A |
| Beta | 1.07 |
| Next Earnings Date | Jul 24, 2023 |
All data is provided by Refinitiv, except for data marked with an asterisk, which is *data provided by Capital.com
| Date | Close | Change | Change (%) | Open | High | Low |
|---|
IVERIC bio, Inc. Events
| Time (UTC) | Country | Event |
|---|---|---|
| Wednesday, November 1, 2023 | ||
| Time (UTC) 12:30 | Country US
| Event Q3 2023 IVERIC bio Inc Earnings Release Q3 2023 IVERIC bio Inc Earnings ReleaseForecast -Previous - |
- Annual
- Quarterly
| 2022 | 2021 | 2020 | 2019 | 2018 | |
|---|---|---|---|---|---|
| Total revenue | 0 | 0 | 0 | 0 | 0 |
| Revenue | 0 | 0 | |||
| Total Operating Expense | 189.906 | 114.757 | 88.736 | 61.272 | -59.651 |
| Selling/General/Admin. Expenses, Total | 72.894 | 29.689 | 25.952 | 21.628 | 23.612 |
| Research & Development | 117.012 | 85.068 | 62.784 | 39.644 | 41.737 |
| Operating Income | -189.906 | -114.757 | -88.736 | -61.272 | 59.651 |
| Interest Income (Expense), Net Non-Operating | 2.264 | 0.245 | 0.5 | 2.151 | 2.389 |
| Other, Net | 0.062 | -0.01 | -0.006 | 0.151 | -0.016 |
| Net Income Before Taxes | -185.211 | -114.522 | -88.242 | -58.97 | 62.024 |
| Net Income After Taxes | -185.211 | -114.522 | -84.547 | -58.859 | 63.087 |
| Net Income Before Extra. Items | -185.211 | -114.522 | -84.547 | -58.859 | 63.087 |
| Net Income | -185.211 | -114.522 | -84.547 | -58.859 | 63.087 |
| Income Available to Common Excl. Extra. Items | -185.211 | -114.522 | -84.547 | -58.859 | 63.087 |
| Income Available to Common Incl. Extra. Items | -185.211 | -114.522 | -84.547 | -58.859 | 63.087 |
| Diluted Net Income | -185.211 | -114.522 | -84.547 | -58.859 | 63.087 |
| Diluted Weighted Average Shares | 121.037 | 101.866 | 74.185 | 42.224 | 37.088 |
| Diluted EPS Excluding Extraordinary Items | -1.5302 | -1.12424 | -1.13968 | -1.39397 | 1.70101 |
| Diluted Normalized EPS | -1.54977 | -1.12424 | -1.13968 | -1.39397 | -0.48973 |
| Total Extraordinary Items | |||||
| Unusual Expense (Income) | 0 | 0 | -125 | ||
| Gain (Loss) on Sale of Assets | 2.369 |
| Mar 2023 | Dec 2022 | Sep 2022 | Jun 2022 | Mar 2022 | |
|---|---|---|---|---|---|
| Total revenue | 0 | 0 | 0 | 0 | 0 |
| Total Operating Expense | 73.841 | 62.971 | 42.512 | 49.753 | 34.67 |
| Selling/General/Admin. Expenses, Total | 31.758 | 27.13 | 17.545 | 16.106 | 12.113 |
| Research & Development | 42.083 | 35.841 | 24.967 | 33.647 | 22.557 |
| Operating Income | -73.841 | -62.971 | -42.512 | -49.753 | -34.67 |
| Interest Income (Expense), Net Non-Operating | 3.461 | 1.449 | 0.2 | 0.482 | 0.133 |
| Other, Net | -1.849 | 0.092 | -0.039 | 0.008 | 0.001 |
| Net Income Before Taxes | -72.229 | -59.061 | -42.351 | -49.263 | -34.536 |
| Net Income After Taxes | -72.229 | -59.061 | -42.351 | -49.263 | -34.536 |
| Net Income Before Extra. Items | -72.229 | -59.061 | -42.351 | -49.263 | -34.536 |
| Net Income | -72.229 | -59.061 | -42.351 | -49.263 | -34.536 |
| Income Available to Common Excl. Extra. Items | -72.229 | -59.061 | -42.351 | -49.263 | -34.536 |
| Income Available to Common Incl. Extra. Items | -72.229 | -59.061 | -42.351 | -49.263 | -34.536 |
| Diluted Net Income | -72.229 | -59.061 | -42.351 | -49.263 | -34.536 |
| Diluted Weighted Average Shares | 137.087 | 125.414 | 120.277 | 119.687 | 118.755 |
| Diluted EPS Excluding Extraordinary Items | -0.52688 | -0.47093 | -0.35211 | -0.4116 | -0.29082 |
| Dividends per Share - Common Stock Primary Issue | 0 | 0 | 0 | 0 | |
| Diluted Normalized EPS | -0.52688 | -0.48982 | -0.35211 | -0.4116 | -0.29082 |
| Gain (Loss) on Sale of Assets | 2.369 |
- Annual
- Quarterly
| 2022 | 2021 | 2020 | 2019 | 2018 | |
|---|---|---|---|---|---|
| Total Current Assets | 662.826 | 387.488 | 216.603 | 128.624 | 133.287 |
| Cash and Short Term Investments | 646.835 | 381.749 | 210.047 | 125.699 | 131.201 |
| Cash & Equivalents | 476.304 | 261.447 | 66.373 | 125.699 | 131.201 |
| Short Term Investments | 170.531 | 120.302 | 143.674 | ||
| Total Receivables, Net | 0 | 1.765 | 0.882 | 0 | |
| Accounts Receivable - Trade, Net | |||||
| Prepaid Expenses | 15.991 | 5.739 | 4.791 | 2.043 | 2.086 |
| Total Assets | 666.823 | 389.358 | 216.754 | 130.187 | 137.165 |
| Property/Plant/Equipment, Total - Net | 2.128 | 1.87 | 0.146 | 0.669 | 0.335 |
| Property/Plant/Equipment, Total - Gross | 3.259 | 2.863 | 1.1 | 1.476 | 1.345 |
| Accumulated Depreciation, Total | -1.131 | -0.993 | -0.954 | -0.807 | -1.01 |
| Long Term Investments | |||||
| Other Long Term Assets, Total | 1.869 | 0 | 0.005 | 0.012 | 0.014 |
| Total Current Liabilities | 35.587 | 28.211 | 25.13 | 12.984 | 13.206 |
| Payable/Accrued | 22.843 | 12.856 | 12.792 | 5.629 | 5.869 |
| Accrued Expenses | 12.744 | 15.355 | 12.338 | 7.355 | 7.337 |
| Notes Payable/Short Term Debt | 0 | 0 | 0 | 0 | 0 |
| Other Current Liabilities, Total | |||||
| Total Liabilities | 132.166 | 28.83 | 25.191 | 12.984 | 13.206 |
| Total Long Term Debt | 96.568 | 0 | 0 | 0 | 0 |
| Other Liabilities, Total | 0.011 | 0.619 | 0.061 | 0 | |
| Total Equity | 534.657 | 360.528 | 191.563 | 117.203 | 123.959 |
| Redeemable Preferred Stock | 0 | 0 | 0 | 0 | 0 |
| Common Stock | 0.137 | 0.115 | 0.09 | 0.05 | 0.041 |
| Additional Paid-In Capital | 1399.56 | 1040.1 | 756.543 | 597.679 | 545.585 |
| Retained Earnings (Accumulated Deficit) | -864.806 | -679.595 | -565.073 | -480.526 | -421.667 |
| Other Equity, Total | -0.229 | -0.09 | 0.003 | ||
| Total Liabilities & Shareholders’ Equity | 666.823 | 389.358 | 216.754 | 130.187 | 137.165 |
| Total Common Shares Outstanding | 136.64 | 115.277 | 90.1208 | 49.6271 | 41.3972 |
| Note Receivable - Long Term | 0 | 0.882 | 3.529 | ||
| Long Term Debt | 96.568 |
| Mar 2023 | Dec 2022 | Sep 2022 | Jun 2022 | Mar 2022 | |
|---|---|---|---|---|---|
| Total Current Assets | 611.543 | 662.826 | 329.478 | 317.222 | 350.967 |
| Cash and Short Term Investments | 599.921 | 646.835 | 320.535 | 311.963 | 345.663 |
| Cash & Equivalents | 467.572 | 476.304 | 153.1 | 141.113 | 191.867 |
| Short Term Investments | 132.349 | 170.531 | 167.435 | 170.85 | 153.796 |
| Total Receivables, Net | 0 | ||||
| Prepaid Expenses | 11.622 | 15.991 | 8.943 | 5.259 | 5.304 |
| Total Assets | 613.407 | 666.823 | 331.79 | 319.756 | 352.705 |
| Property/Plant/Equipment, Total - Net | 1.864 | 2.128 | 2.312 | 2.534 | 1.738 |
| Other Long Term Assets, Total | 0 | 1.869 | 0 | ||
| Total Current Liabilities | 39.374 | 35.587 | 24.588 | 26.479 | 19.166 |
| Payable/Accrued | 18.026 | 22.843 | 11.601 | 8.178 | 5.294 |
| Accrued Expenses | 21.348 | 12.744 | 12.987 | 18.301 | 13.872 |
| Notes Payable/Short Term Debt | 0 | 0 | 0 | 0 | 0 |
| Total Liabilities | 136.361 | 132.166 | 72.264 | 26.81 | 19.551 |
| Total Long Term Debt | 96.987 | 96.568 | 47.649 | 0 | 0 |
| Other Liabilities, Total | 0 | 0.011 | 0.027 | 0.331 | 0.385 |
| Total Equity | 477.046 | 534.657 | 259.526 | 292.946 | 333.154 |
| Redeemable Preferred Stock | 0 | 0 | 0 | 0 | 0 |
| Common Stock | 0.137 | 0.137 | 0.121 | 0.117 | 0.116 |
| Additional Paid-In Capital | 1414.04 | 1399.56 | 1065.55 | 1056.75 | 1047.56 |
| Retained Earnings (Accumulated Deficit) | -937.035 | -864.806 | -805.745 | -763.394 | -714.131 |
| Other Equity, Total | -0.099 | -0.229 | -0.395 | -0.528 | -0.394 |
| Total Liabilities & Shareholders’ Equity | 613.407 | 666.823 | 331.79 | 319.756 | 352.705 |
| Total Common Shares Outstanding | 137.25 | 136.64 | 120.573 | 116.874 | 115.974 |
| Property/Plant/Equipment, Total - Gross | 3.259 | ||||
| Accumulated Depreciation, Total | -1.131 | ||||
| Long Term Debt | 96.987 | 96.568 | 47.649 |
- Annual
- Quarterly
| 2022 | 2021 | 2020 | 2019 | 2018 | |
|---|---|---|---|---|---|
| Net income/Starting Line | -185.211 | -114.522 | -84.547 | -58.859 | 63.087 |
| Cash From Operating Activities | -163.771 | -98.559 | -66.097 | -48.49 | -41.911 |
| Cash From Operating Activities | 0.138 | 0.039 | 0.143 | 0.162 | 0.183 |
| Deferred Taxes | 0 | 0 | |||
| Non-Cash Items | 26.019 | 12.427 | 8.785 | 9.115 | -108.309 |
| Cash Taxes Paid | 0 | 1.765 | 3.327 | 1.893 | 2.467 |
| Changes in Working Capital | -4.717 | 3.497 | 9.522 | 1.092 | 3.128 |
| Cash From Investing Activities | -50.277 | 21.298 | -143.81 | 0.15 | 0 |
| Capital Expenditures | -0.736 | -0.361 | 0 | ||
| Other Investing Cash Flow Items, Total | -49.541 | 21.659 | -143.81 | 0.15 | 0 |
| Cash From Financing Activities | 428.905 | 272.335 | 150.581 | 42.838 | 6.14 |
| Financing Cash Flow Items | |||||
| Issuance (Retirement) of Stock, Net | 332.803 | 272.335 | 150.581 | 42.838 | 6.14 |
| Net Change in Cash | 214.857 | 195.074 | -59.326 | -5.502 | -35.771 |
| Issuance (Retirement) of Debt, Net | 96.102 |
| Mar 2023 | Dec 2022 | Sep 2022 | Jun 2022 | Mar 2022 | |
|---|---|---|---|---|---|
| Net income/Starting Line | -72.229 | -185.211 | -126.15 | -83.799 | -34.536 |
| Cash From Operating Activities | -50.593 | -163.771 | -114.537 | -73.421 | -37.512 |
| Cash From Operating Activities | 0.07 | 0.138 | 0.08 | 0.045 | 0.021 |
| Non-Cash Items | 11.029 | 26.019 | 18.952 | 12.314 | 5.686 |
| Changes in Working Capital | 10.537 | -4.717 | -7.419 | -1.981 | -8.683 |
| Cash From Investing Activities | 39.272 | -50.277 | -48.41 | -51.794 | -34.148 |
| Other Investing Cash Flow Items, Total | 39.505 | -49.541 | -47.97 | -51.583 | -34.032 |
| Cash From Financing Activities | 2.589 | 428.905 | 54.6 | 4.881 | 2.08 |
| Issuance (Retirement) of Stock, Net | 2.589 | 332.803 | 7.123 | 4.881 | 2.08 |
| Net Change in Cash | -8.732 | 214.857 | -108.347 | -120.334 | -69.58 |
| Cash Taxes Paid | 0 | 0 | 0 | ||
| Capital Expenditures | -0.233 | -0.736 | -0.44 | -0.211 | -0.116 |
| Issuance (Retirement) of Debt, Net | 96.102 | 47.477 | |||
| Cash Interest Paid | 2.406 |
IVERIC bio, Inc. Company profile
About IVERIC bio Inc
IVERIC bio, Inc. is a biopharmaceutical company. The Company is focused on the discovery and development ofl treatments for retinal diseases with unmet medical needs. Its lead asset clinical stage product candidate Zimura, a complement C5 inhibitor. Zimura is targeting diseases include: Geographic Atrophy (GA), intermediate (age-related macular degeneration) AMD, and autosomal recessive Stargardt disease (STGD1). It is also developing preclinical product candidate IC-500, a High temperature requirement A serine peptidase 1 protein (HtrA1) inhibitor for GA and potentially other age-related retinal diseases. Its portfolio also includes two preclinical stage gene therapy product candidates, which include IC-100 and IC-200 and several ongoing gene therapy research programs. The Company is developing IC-100 for rhodopsin-mediated autosomal dominant retinitis pigmentosa (RHO-adRP) and IC-200 for bestrophin-1 (BEST1) related IRDs.
Financial summary
BRIEF: For the fiscal year ended 31 December 2021, IVERIC bio Inc revenues was not reported. Net loss increased 35% to $114.5M. Higher net loss reflects Reasearch and development increase of 34% to $78.5M (expense), General and administrative increase of 15% to $25M (expense), Stock-based Compensation in R&D increase of 57% to $6.5M (expense). Basic Earnings per Share excluding Extraordinary Items increased from -$1.14 to -$1.12.
Equity composition
Common Stock, $0.001 Par, 09/13, 30,110,817 issd., Insiders own approx. 74.76%
| Industry: | Biotechnology & Medical Research (NEC) |
8 Sylvan Way
Suite 2372
PARSIPPANY
NEW JERSEY 07054
US
News
EUR/USD tests key support
EUR/USD is currently testing a key support level after the Federal Reserve indicated a potential extension of higher interest rates.
14:32, 21 September 2023
BoE leaves rates unchanged, GBP drops further as investors look for more clarity
The Bank of England has left rates unchanged at 5.25% with a 5-4 vote split after CPI dropped more than expected in August
11:45, 21 September 2023
GBP softer after CPI surprise, JPY focused on any further hints from Ueda
GBP drops after a softer CPI reading scares investors about the BoE intentions. JPY on the lookout for further policy tweaks from Governor Ueda.
12:42, 20 September 2023
How to Trade The Break & Retest
In this week's instalment, we delve into the Break & Retest pattern—a strategic approach to navigating breakout trades. If you've wrestled with the frustration of false breakouts, incorporating this pattern into your trading toolkit may help you overcome this challenge and put you on the path to becoming a more confident and consistent trader.
11:59, 20 September 2023
Cable coils near lows ahead of Fed and BoE rate decisions
It’s a big week for Cable (GBP/USD) as both the Federal Reserve and the Bank of England are set to make crucial rate decisions.
14:16, 19 September 2023
FTSE 100 Technical Outlook - 18 September 2023
In prior technical outlooks, we highlighted the importance of staying alert in sleepy markets, and last Thursday’s developments on the FTSE 100 serve as a prime illustration of this principle.
06:55, 19 September 2023
Market Analysis: FTSE 100 boosted by ECB rate hike end and iron ore rally
The FTSE 100 rose over 2% on Thursday as the ECB announced no more rate hikes for now.
13:46, 15 September 2023People also watch
Still looking for a broker you can trust?
Join the 555.000+ traders worldwide that chose to trade with Capital.com